3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
4
Breast Neoplasms
4
Myeloproliferative Disorders
3
Melanoma
3
Skin Neoplasms
2
Lung Neoplasms
2
Thrombosis
1
Pyruvate Kinase Deficiency of Red Cells
1
Precancerous Conditions
1
Pancreatic Cyst
1
Neuroendocrine Tumors
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Myelitis, Transverse
1
Myasthenia Gravis
1
Multiple Sclerosis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphatic Metastasis
1
Locally Advanced Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Interventions
Pluvicto
2
radium Ra 223 dichloride
1
olaparib
1
enzalutamide
1
alovudine
1
Radium-223
1
Nivolumab
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
30 days
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled